Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer. Joensuu H. JAMA 2024 Dec 13. doi: 10.1001/jama.2024.25927.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Joensuu H. Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer. JAMA 2024 Dec 13. doi: 10.1001/jama.2024.25927.
PMID: 39671279